Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...

Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...

Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

BioNTech (NASDAQ:BNTX) stock rose 1.9% after Evercore ISI upgraded its stance on the drugmaker to ‘outperform’ from ‘in line’ ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says ...

Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been “growing increasingly constructive for some time now.” The upgrade ...

LONDON — Robert F. Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies ...

The stocks for three pharmaceutical companies heavily involved in the production of vaccines fell drastically by market close ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...

With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...